Literature DB >> 10692172

Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases.

J Iwata1, C D Fletcher.   

Abstract

Although 'aberrant' expression of the epithelial markers, cytokeratin (CK) and epithelial membrane antigen (EMA), in leiomyosarcoma has been described previously, there has not been a study of this phenomenon with clinicopathological correlation in a large series of lesions at different anatomical sites. We investigated systematically the immunohistochemical reactivity for CK and EMA in 100 cases of leiomyosarcoma. CK and EMA were positive in 38% and 44% of the cases, respectively. Although staining was usually focal, extensive immunoreactivity was observed in 11% with CK and 6% with EMA. There was no correlation between immunoreactivity for CK and EMA in leiomyosarcomas and non-neoplastic smooth muscle at the same location. Immunoreactivity for CK and EMA was not correlated with the location, age, sex, histological grade, or histological features, except for more frequent EMA positivity in vascular and uterine tumors than in soft tissue cases. These results indicate that CK and/or EMA-positive leiomyosarcomas do not have distinctive clinicopathological features differing from those of negative cases. However, the considerable frequency of immunoreactivity for these epithelial markers in leiomyosarcoma, occasionally with diffuse and strong immunopositivity, should be recognized as a potentially serious diagnostic pitfall in the differential diagnosis of other malignant spindle cell neoplasms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10692172     DOI: 10.1046/j.1440-1827.2000.01001.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  20 in total

Review 1.  Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis.

Authors:  Markku Miettinen
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

Review 2.  Fibromyxoma of the Jaw: Case Report and Review of the Literature.

Authors:  Thabet Alhousami; Amarpreet Sabharwal; Shivane Gupta; Alfredo Aguirre; Etern Park; Jill M Kramer
Journal:  Head Neck Pathol       Date:  2017-05-16

3.  Limb saving procedure in metastatic leiomyosarcoma of the femoral vein: case report and literature review.

Authors:  Mario Valle; Giovanni Battista Levi Sandri; F Carboni; O Federici; G Pizzi; R Covello; S Carpano; A Garofalo
Journal:  Indian J Surg       Date:  2014-01-19       Impact factor: 0.656

4.  Inoperable Left Renal Vein Leiomyosarcoma Refractory to Chemotherapy Invades Inferior Vena Cava and Right Atrium: A Case Report.

Authors:  Geoffrey Lindblad; Stephanie Prater; Sotiris E Chaniotakis; James Banks
Journal:  Cureus       Date:  2021-02-06

5.  Pseudomyogenic Hemangioendothelioma: A Vascular Tumor Previously Undescribed in the Oral Cavity.

Authors:  Yeshwant B Rawal; Kenneth M Anderson; Thomas B Dodson
Journal:  Head Neck Pathol       Date:  2016-11-22

Review 6.  Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.

Authors:  Esther Oliva
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

7.  A primary leiomyosarcoma of bone containing pseudoepithelial plexiform elements.

Authors:  A Rigopoulou; M Vlychou; S J Ostlere; C L M H Gibbons; N A Athanasou
Journal:  Skeletal Radiol       Date:  2007-05-05       Impact factor: 2.199

8.  Expression of smooth muscle markers in so called malignant fibrous histiocytomas.

Authors:  T Hasegawa; F Hasegawa; T Hirose; T Sano; Y Matsuno
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

9.  Primary renal leiomyosarcoma: A diagnostic challenge.

Authors:  Shashi Dhawan; Prem Chopra; Sanjay Dhawan
Journal:  Urol Ann       Date:  2012-01

10.  Expression patterns for Bcl-2, EMA, β-catenin, E-cadherin, PAX8, and MIB1 in thymomas.

Authors:  David Suster; James A Miller; German Pihan; A Craig Mackinnon; Saul Suster
Journal:  Mod Pathol       Date:  2021-06-16       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.